Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Espero BioPharma

Espero is focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control.

  • Date:Monday, February 11
  • Time:10:30 AM - 10:45 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23520
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Seeking new investors
  • Company Website:www.esperobio.com
  • Company HQ City:Jacksonville
  • Company HQ State:Florida
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$40,000,000
  • Size of Last Investment Round:$23,000,000
  • Previous and Current Investors:Hercules Bioventure Partners, Capital TEN II, Pohl Boskamp, Lee's Pharma, founders
  • CEO/Top Company Official:Quang Pham
  • Year Founded:2014
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development:Tecarfarin
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):0
  • Additional Information/Comments:Late-stage clinical platform of novel chemical entities that have metabolism independent of cytochrome P450 (CYP450) enzymes Phase 3 ready tecarfarin, reversible oral anticoagulant (OAC) Budiodarone, anti-arrhythmic candidate with two Phase 2 studies completed Each with blockbuster potential>$1 billion revenue annually $10 billion U.S. OAC market and growing Tecarfarin only requires a single 1,000 patient Phase 3 pivotal trial approved under FDA Special Protocol Assessment (SPA).
Speakers
Lee Golden
Espero BioPharma
Back